The oral formulation of gemcabene is being developed for the treatment of hypercholesterolaemia which is an excess of cholesterol in the bloodstream. Three of the five patients tested showed decreases in TG levels while one patient discontinued treatment.
Gemphire shares were trading down 22.5% at 92 cents at time of publication.
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.